In addition to the characterizations and assays performed by generic sponsors, FDA’s internal laboratory developed and performed its own testing97 of multiple batches of Copaxone, the proposed generic glatiramer acetate injection, glatiramer acetate-like products marketed outside of the United States,98 and negative controls, in each case using high-resolution analytical techniques.
Market Data 
Markets 
AI
